Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Advertisements

Figure 1 The heterogenous landscape of triple-negative breast cancer

Nat. Rev. Urol. doi: /nrurol

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 1 Concept of the therapeutic index

George J. Netto, Marie-Lisa Eich, Sooryanarayana Varambally

Figure 1 Cellular processes involved in cancer development

Figure 3 Birt–Hogg–Dubé (BHD) renal tumour histology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Urol. doi: /nrurol

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Representative images from a right radical

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 1 The development process of the Asian

Figure 1 Illustration of three complex somatic mutational phenomena

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 13 Proposed management of bladder cancer with variant histology

Figure 1 Anatomy of the venous drainage from the testes

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Urol. doi: /nrurol

Frozen sections of (A) fetal intestine, (B) tonsil, and (C) mantle cell lymphoma, stained using anti-CD3 (immunoperoxidase; brown) followed by anti-CD5.

Figure 6 Image sequence demonstrating coronal cuts on MRI

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Urol. doi: /nrurol

Figure 3 Differences in renal cell carcinoma (RCC) between genders

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 6 The hexosamine biosynthetic pathway (HBP)

Nat. Rev. Urol. doi: /nrurol

Figure 3 Examples of gene expression heterogeneity

Figure 2 Frequency and overlap of alterations

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 4 Algorithm for when to determine PTEN

Receptor tyrosine kinase (RTK) responds to external stimuli including extracellular matrix components and chemokines and subsequently activates phosphoinositide.

Rat endometrial hyperplasia (A) has increased glandular crowding, increased glandular size, increased glandular complexity, and increased epithelial nuclear.

Activation of membrane-associated Akt is associated with loss of apoptosis in TgAPT121;Pten+/− prostates. Activation of membrane-associated Akt is associated.

PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2018.9 Figure 3 Heterogeneous immunohistochemical expression of ERG and PTEN in prostate tumours Figure 3 | Heterogeneous immunohistochemical expression of ERG and PTEN in prostate tumours. a | Heterogeneous phosphatase and tensin homologue (PTEN) loss is observed in some tumour glands (N), with intact staining in other tumour glands (P), whereas the same areas are uniformly positive for ERG expression, indicating that clonal ERG genomic rearrangement is probably present with subsequent subclonal PTEN loss. b | Heterogeneous PTEN loss is seen in some tumour glands (N), with intact staining in other tumour glands (P), whereas the same areas are uniformly negative for ERG expression (ERG genomic rearrangement is absent). Jamaspishvili, T. et al. (2018) Clinical implications of PTEN loss in prostate cancer Nat. Rev. Urol. doi:10.1038/nrurol.2018.9